Last Updated 28 October 2014
Psoriasis is a skin disorder that, depending on its severity and location on the body, can have a major impact on patients’ quality of life. It is generally characterized as mild or moderate to severe and can be accompanied by the debilitating joint disease psoriatic arthritis (PsA). We expect the psoriasis therapy market to experience substantial growth over the 2013-2023 forecast period as a result of the launches of several new therapies and increasing drug-treatment rates.
Questions Answered in This Report:
- The interleukin-12 (IL-12)/23 inhibitor ustekinumab (Janssen’s Stelara) has experienced strong uptake since its launch for psoriasis in 2009 and has established an earlier position in dermatologists’ treatment algorithm on the strength of its favorable efficacy and safety profile and convenient dosing. How are dermatologists incorporating this agent in their treatment of patients with moderate to severe psoriasis? How will the entry of agents with novel mechanisms of action competing for use in the TNF-refractory population affect ustekinumab’s growth trajectory?
- The launch of emerging therapies with novel mechanisms of action—three IL-17 inhibitors (Novartis’s secukinumab, Eli Lilly’s ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin’s brodalumab); an oral Janus kinase inhibitor (Pfizer’s tofacitinib [Xeljanz]); and the IL-23 inhibitors (Sun Pharma/Merck’s tildrakizumab and Janssen’s guselkumab)—will increase competition for patient share in the TNF-α-refractory space beginning in 2015. Celgene’s oral phosphodiesterase-4 (PDE-4) inhibitor apremilast will also compete within the moderate to severe patient segment. What is the likely positioning of each of these agents based on their efficacy and safety profiles? Which current therapies are they most likely to replace in the treatment algorithm for psoriasis?
- Biosimilar versions of the TNF-α inhibitors will become available in all the major markets during the forecast period. We project that biosimilars will be priced at a discount to their branded counterparts, and we expect that positive clinical trial data from biosimilars in psoriasis will lead to more-aggressive erosion of branded agents over the forecast period. How will the availability of biosimilars affect the uptake of biologics in psoriasis? What is the sales potential of novel, premium-priced oral agents given the anticipated availability of biosimilar TNF-α inhibitors?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 32 country-specific interviews with thought-leading dermatologists.
Epidemiology: Diagnosed prevalence of four psoriasis subpopulations—symptom-free, mild, moderate, severe.
Population segments in market forecast: Moderate-to-severe psoriasis and mild psoriasis.
Emerging therapies: Phase II: 5 drugs; Phase III: 4 drugs; preregistration: 1 drug; registered: 1 drug.
Courtney Walls, M.P.H.